CA2514547A1 - Agonistes de recepteurs - Google Patents
Agonistes de recepteurs Download PDFInfo
- Publication number
- CA2514547A1 CA2514547A1 CA002514547A CA2514547A CA2514547A1 CA 2514547 A1 CA2514547 A1 CA 2514547A1 CA 002514547 A CA002514547 A CA 002514547A CA 2514547 A CA2514547 A CA 2514547A CA 2514547 A1 CA2514547 A1 CA 2514547A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- optionally substituted
- compound
- ring
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-019272 | 2003-01-28 | ||
JP2003019272 | 2003-01-28 | ||
JP2003-124311 | 2003-04-28 | ||
JP2003124311 | 2003-04-28 | ||
PCT/JP2004/000706 WO2004067008A1 (fr) | 2003-01-28 | 2004-01-27 | Agonistes de recepteurs |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2514547A1 true CA2514547A1 (fr) | 2004-08-12 |
Family
ID=32828895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002514547A Abandoned CA2514547A1 (fr) | 2003-01-28 | 2004-01-27 | Agonistes de recepteurs |
Country Status (4)
Country | Link |
---|---|
US (1) | US7625887B2 (fr) |
EP (1) | EP1591120A4 (fr) |
CA (1) | CA2514547A1 (fr) |
WO (1) | WO2004067008A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005116653A2 (fr) * | 2004-04-13 | 2005-12-08 | Arena Pharmaceuticals, Inc. | Recepteur couple a une proteine g humaine et modulateurs associes utilises dans le traitement de l'hyperglycemie et des troubles afferents |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006070718A1 (fr) * | 2004-12-27 | 2006-07-06 | Banyu Pharmaceutical Co., Ltd. | Medicaments destines a des maladies accompagnant des modifications des acides biliaires totaux ou des troubles du metabolisme lipidique et procede de criblage desdits medicaments |
GB0511844D0 (en) * | 2005-06-10 | 2005-07-20 | Novartis Ag | Organic compounds |
CA2621273C (fr) | 2005-09-12 | 2014-07-29 | Actelion Pharmaceuticals Ltd | Composition pharmaceutique stable a pyrimidine-sulfamide |
EP2018863B9 (fr) * | 2006-05-16 | 2015-02-18 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique fusionné et utilisation |
KR20090021313A (ko) | 2006-07-17 | 2009-03-02 | 노파르티스 아게 | 면역조절제로서 사용하기 위한 담즙산 아미드의 술포닐아미노카르보닐 유도체 |
AU2007325315A1 (en) * | 2006-11-28 | 2008-06-05 | Kalypsys Inc | Heterocyclic modulators of TGR5 |
WO2008067219A2 (fr) * | 2006-11-29 | 2008-06-05 | Kalypsys, Inc. | Modulateurs quinazolinones de tgr5 |
WO2008097976A1 (fr) * | 2007-02-09 | 2008-08-14 | Kalypsys, Inc. | Modulateurs hétérocycliques de tgr5 pour le traitement des maladies |
JP2010526825A (ja) | 2007-05-10 | 2010-08-05 | エーエムアール テクノロジー インコーポレイテッド | アリール置換およびヘテロアリール置換テトラヒドロベンゾ−1,4−ジアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用 |
WO2009063991A1 (fr) | 2007-11-15 | 2009-05-22 | Takeda Pharmaceutical Company Limited | Dérivé de pyridooxazépine et son utilisation |
EP2242745A1 (fr) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Nouvelles imidazolidines substituées par un phényle, procédé de production, médicaments contenant ces composés et leur utilisation |
WO2010016552A1 (fr) | 2008-08-07 | 2010-02-11 | 武田薬品工業株式会社 | Agent thérapeutique pour le syndrome du côlon irritable |
WO2010016846A1 (fr) * | 2008-08-08 | 2010-02-11 | Kalypsys, Inc. | Modulateurs hétérocycliques de tgr5 pour le traitement d'une maladie |
CA2744189C (fr) | 2008-11-19 | 2016-10-11 | Intercept Pharmaceuticals, Inc. | Modulateurs de tgr5 et leur procede d'utilisation |
ES2774368T3 (es) | 2008-11-19 | 2020-07-20 | Intercept Pharmaceuticals Inc | Moduladores de TGR5 y métodos de uso de los mismos |
AR077094A1 (es) | 2009-06-15 | 2011-08-03 | Takeda Pharmaceutical | Derivados de pirazinooxazepina, composiciones farmaceuticas y su uso en el tratamiento de un sintoma del aparato urinario inferior, obesidad y/o prolapso de organos |
JP5645823B2 (ja) | 2009-08-04 | 2014-12-24 | 武田薬品工業株式会社 | チエノオキサゼピン誘導体 |
WO2011157827A1 (fr) | 2010-06-18 | 2011-12-22 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
WO2012061754A2 (fr) * | 2010-11-05 | 2012-05-10 | The Broad Institute, Inc. | Composés et procédés pour traiter des maladies auto-immunes |
WO2012082947A1 (fr) | 2010-12-16 | 2012-06-21 | Irm Llc | Composés et compositions en tant qu'agonistes de tgr5 |
EP2567959B1 (fr) | 2011-09-12 | 2014-04-16 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
EA201490807A1 (ru) | 2011-10-21 | 2014-07-30 | Торрент Фармасьютикалз Лимитед | Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1 |
WO2013064231A1 (fr) | 2011-10-31 | 2013-05-10 | Phenex Pharmaceuticals Ag | Sulfonamides à sept chaînons comme modulateurs des récepteurs gamma orphelins associés à un récepteur de l'acide rétinoïque (rorγ, nr1f3) |
WO2013102929A1 (fr) | 2011-12-26 | 2013-07-11 | Cadila Healthcare Limited | Nouveaux composés pour le traitement du diabète, de l'obésité ou de troubles associés |
WO2014100021A1 (fr) | 2012-12-17 | 2014-06-26 | Exelixis, Inc. | Agonistes de tgr5 : composés d'imidazole et de triazole contenant un azote quaternaire |
JP2016521744A (ja) | 2013-06-13 | 2016-07-25 | ファスト フォワード ファーマスーティカルズ ベー.フェー. | 追加化合物が胆汁酸、胆汁酸誘導体、tgr5受容体作動物質、fxr作動物質またはそれらの組合せである、慢性炎症の治療および消化器癌または線維症の予防のためのcd40シグナル伝達阻害物質および追加化合物 |
US10077241B2 (en) | 2014-04-15 | 2018-09-18 | Jansen Pharmaceutica Nv | Tetrahydro-benzoimidazolyl modulators of TGR5 |
TW201729814A (zh) * | 2015-12-24 | 2017-09-01 | 武田藥品工業股份有限公司 | 固形製劑 |
TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
CN111440162A (zh) * | 2020-04-01 | 2020-07-24 | 邱曲真 | 噻唑二氢萘类衍生物及其在代谢性疾病中的应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3555034A (en) * | 1968-06-18 | 1971-01-12 | American Home Prod | Certain 5,6,7,8-tetrahydro-1,6-naphthyridin-2-ol esters |
ES431307A1 (es) | 1973-11-16 | 1976-09-01 | Thomae Gmbh Dr K | Procedimiento para la preparacion de nuevos derivados de quinoleina. |
US4220778A (en) * | 1978-10-30 | 1980-09-02 | G. D. Searle & Co. | 8-Aryl-1,2,3,4-tetrahydroisoquinoline and derivatives thereof |
US4329341A (en) | 1980-11-26 | 1982-05-11 | Richter Gedeon Vegyeszeti Gyar Rt | 5-Phenyl-1,3,4,5-tetrahydro-2H-1,4-benzodiazepin-2-ones, and pharmaceutical compositions containing them |
US4820834A (en) * | 1984-06-26 | 1989-04-11 | Merck & Co., Inc. | Benzodiazepine analogs |
CA1332410C (fr) | 1984-06-26 | 1994-10-11 | Roger M. Freidinger | Analogues de benzodiazepines |
DE3431195A1 (de) | 1984-08-24 | 1986-03-06 | Troponwerke GmbH & Co KG, 5000 Köln | Neue benzodiazepine, verfahren zu ihrer herstellung sowie ihre verwendung |
US5324726A (en) | 1989-12-18 | 1994-06-28 | Merck & Co., Inc. | Benzodiazepine analogs |
US5137890A (en) | 1990-02-14 | 1992-08-11 | Ortho Pharmaceutical Corporation | 4-phenyl tetrahydropyrido(4,3-d)pyrimidines |
EP0567026B1 (fr) | 1992-04-20 | 2003-03-26 | Takeda Chemical Industries, Ltd. | Dérivés de 4,1-benzoxazepine comme inhibiteurs de la synthétase du squalène et leur application dans le traitement d'hypercholesteremie et comme fongicides |
US5441952A (en) * | 1993-04-05 | 1995-08-15 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
WO1995028399A1 (fr) * | 1994-04-15 | 1995-10-26 | Glaxo Wellcome Inc. | Procede d'induction d'une activite agoniste de la cholecystokinine a l'aide de composes 1,4-benzodiazepines |
TW401301B (en) | 1994-10-07 | 2000-08-11 | Takeda Chemical Industries Ltd | Antihypertriglyceridemic composition |
TW394773B (en) | 1995-03-24 | 2000-06-21 | Takeda Chemical Industries Ltd | Cyclic compounds for antagonizing tachykinin receptor, substance p receptor and neurokinin a receptor, their production and pharmaceutical composition |
CN1072649C (zh) * | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
JPH09291034A (ja) * | 1996-02-27 | 1997-11-11 | Yoshitomi Pharmaceut Ind Ltd | 縮合ピリジン化合物およびその医薬としての用途 |
CN1252795A (zh) * | 1997-04-21 | 2000-05-10 | 武田药品工业株式会社 | 4,1-苯并氧氮杂、它们的类似物和它们作为抑生长素***的用途 |
JPH11209356A (ja) * | 1997-04-21 | 1999-08-03 | Takeda Chem Ind Ltd | 縮合環化合物、その製造法及び剤 |
CN1173946C (zh) | 1998-01-29 | 2004-11-03 | 阿温蒂斯药物公司 | 制备n-[(脂族或芳族)羰基]-2-氨基乙酰胺化合物和环化化合物的方法 |
KR20010041991A (ko) | 1998-03-19 | 2001-05-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 복소환식 화합물, 그의 제조법 및 타키키닌 수용체길항약으로서의 용도 |
US6150357A (en) | 1999-05-10 | 2000-11-21 | Merck & Co., Inc. | Potassium channel agonists |
WO2001055121A1 (fr) * | 2000-01-28 | 2001-08-02 | Kaken Pharmaceutical Co., Ltd. | Dérivés d'azépine |
WO2001077325A1 (fr) | 2000-04-12 | 2001-10-18 | Takeda Chemical Industries, Ltd. | Nouvelle proteine de recepteur couple aux proteines g et adn de celle-ci |
US7198914B2 (en) * | 2000-11-17 | 2007-04-03 | Banyu Pharmaceutical Co., Ltd. | Guanosine triphosphate (GTP)-binding protein-coupled receptor protein, BG37 |
WO2002084286A1 (fr) | 2001-04-12 | 2002-10-24 | Takeda Chemical Industries, Ltd. | Procede de criblage |
AU2002346048A1 (en) * | 2001-06-07 | 2002-12-16 | Merck And Co., Inc. | Benzodiazepine bradykinin antagonists |
CA2451163A1 (fr) * | 2001-06-28 | 2003-01-09 | Takeda Chemical Industries, Ltd. | Medicaments destines a la prevention/au traitement de troubles fonctionnels des organes et du dysfonctionnement des organes |
AU2003287053A1 (en) * | 2002-10-10 | 2004-05-04 | Elian Pharmaceuticals Inc | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists |
AU2003277663A1 (en) | 2002-11-12 | 2004-06-03 | Takeda Pharmaceutical Company Limited | Screening method |
-
2004
- 2004-01-27 CA CA002514547A patent/CA2514547A1/fr not_active Abandoned
- 2004-01-27 US US10/543,997 patent/US7625887B2/en not_active Expired - Fee Related
- 2004-01-27 WO PCT/JP2004/000706 patent/WO2004067008A1/fr not_active Application Discontinuation
- 2004-01-27 EP EP04705536A patent/EP1591120A4/fr not_active Withdrawn
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005116653A2 (fr) * | 2004-04-13 | 2005-12-08 | Arena Pharmaceuticals, Inc. | Recepteur couple a une proteine g humaine et modulateurs associes utilises dans le traitement de l'hyperglycemie et des troubles afferents |
WO2005116653A3 (fr) * | 2004-04-13 | 2006-05-18 | Arena Pharm Inc | Recepteur couple a une proteine g humaine et modulateurs associes utilises dans le traitement de l'hyperglycemie et des troubles afferents |
Also Published As
Publication number | Publication date |
---|---|
US20060199795A1 (en) | 2006-09-07 |
WO2004067008A1 (fr) | 2004-08-12 |
EP1591120A4 (fr) | 2009-06-10 |
US7625887B2 (en) | 2009-12-01 |
EP1591120A1 (fr) | 2005-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7625887B2 (en) | Receptor agonists | |
EP2663559B1 (fr) | Dérivés d'oxazine et leur utilisation dans le traitement de maladies neurologiques | |
US7829597B2 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
JP5711813B2 (ja) | βセクレターゼ(BACE)の阻害剤として有用な5,6−ジヒドロ−2H−[1,4]オキサジン−3−イル−アミン誘導体 | |
CN115667250A (zh) | 杂环glp-1激动剂 | |
JP2006056881A (ja) | 縮合環化合物 | |
TW202142538A (zh) | 雜環glp-1促效劑 | |
TW201341385A (zh) | 咪唑[1,2-b]噠嗪基化合物、包含其之組成物及其使用方法 | |
TW201004944A (en) | Crystalline compound | |
KR20220004103A (ko) | 4H-피롤로[3,2-c]피리딘-4-온 화합물 | |
WO2020161257A1 (fr) | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5-tétrahydro-4h-pyrrolo[3,2-c]pyridin-4-one en tant qu'inhibiteurs de csnk1 | |
JP5361733B2 (ja) | ピリドオキサゼピン誘導体およびその用途 | |
CN101827820A (zh) | 氨基吡唑酰胺衍生物 | |
JP2022516685A (ja) | ホスファターゼ結合化合物およびそれらを使用する方法 | |
EP3063139B1 (fr) | Composé hétérocyclique | |
WO2018213491A9 (fr) | Méthodes de traitement de l'épilepsie et de troubles neurodéveloppementaux | |
KR20190066052A (ko) | 나프티리디논 유도체 및 부정맥의 치료에서의 이들의 용도 | |
CN103261176B (zh) | 1,4-氧杂氮杂环庚烷衍生物 | |
JP2004346059A (ja) | 受容体作動薬 | |
JPWO2008007664A1 (ja) | 二環性複素環化合物およびその用途 | |
US20130281435A1 (en) | Therapeutic agent for irritable bowel syndrome | |
US7795267B2 (en) | Bicyclic piperazine compound having TGR23 antagonistic activity | |
CA3201333A1 (fr) | Derives de n-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl)oxy)ethyl]prop-2-enamide et composes similaires utilises en tant qu'inhibiteur s d'egfr pour le traitement du cancer | |
TW202208349A (zh) | 雜環化合物 | |
JP2014159375A (ja) | アゼパン化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |